JP2024527220A5 - - Google Patents
Info
- Publication number
- JP2024527220A5 JP2024527220A5 JP2023566569A JP2023566569A JP2024527220A5 JP 2024527220 A5 JP2024527220 A5 JP 2024527220A5 JP 2023566569 A JP2023566569 A JP 2023566569A JP 2023566569 A JP2023566569 A JP 2023566569A JP 2024527220 A5 JP2024527220 A5 JP 2024527220A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pro
- peptide
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210086014A KR20230004135A (ko) | 2021-06-30 | 2021-06-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| KR10-2021-0086014 | 2021-06-30 | ||
| PCT/KR2022/009449 WO2023277620A1 (ko) | 2021-06-30 | 2022-06-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527220A JP2024527220A (ja) | 2024-07-24 |
| JP2024527220A5 true JP2024527220A5 (https=) | 2025-07-07 |
Family
ID=84690475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566569A Pending JP2024527220A (ja) | 2021-06-30 | 2022-06-30 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240293512A1 (https=) |
| EP (1) | EP4364750A4 (https=) |
| JP (1) | JP2024527220A (https=) |
| KR (1) | KR20230004135A (https=) |
| CN (1) | CN117615775A (https=) |
| AU (1) | AU2022302809A1 (https=) |
| BR (1) | BR112023022445A2 (https=) |
| CA (1) | CA3216330A1 (https=) |
| IL (1) | IL308347A (https=) |
| MX (1) | MX2023012935A (https=) |
| WO (1) | WO2023277620A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| ES2983409T3 (es) * | 2016-03-10 | 2024-10-23 | Medimmune Ltd | Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| JOP20190095A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| EP3573651A4 (en) * | 2017-01-27 | 2020-10-14 | NGM Biopharmaceuticals, Inc. | GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE |
| WO2020071865A1 (ko) * | 2018-10-04 | 2020-04-09 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
| CN113453703A (zh) * | 2018-12-21 | 2021-09-28 | 韩美药品株式会社 | 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物 |
| MX2021008010A (es) * | 2018-12-31 | 2021-10-13 | Coherus Biosciences Inc | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). |
| DK3936142T3 (da) * | 2019-06-28 | 2024-03-25 | Hanmi Pharmaceutical Co Ltd | Tredobbelt agonist med aktivitet med hensyn til alle glucagon-, GLP-1- og GLP-receptorer til behandling af leversygdom |
| EP4197560A4 (en) * | 2020-08-14 | 2025-11-26 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising a persistent triple activator conjugate used as the active ingredient. |
-
2021
- 2021-06-30 KR KR1020210086014A patent/KR20230004135A/ko active Pending
-
2022
- 2022-06-30 JP JP2023566569A patent/JP2024527220A/ja active Pending
- 2022-06-30 EP EP22833674.9A patent/EP4364750A4/en active Pending
- 2022-06-30 BR BR112023022445A patent/BR112023022445A2/pt unknown
- 2022-06-30 CN CN202280042772.4A patent/CN117615775A/zh active Pending
- 2022-06-30 CA CA3216330A patent/CA3216330A1/en active Pending
- 2022-06-30 IL IL308347A patent/IL308347A/en unknown
- 2022-06-30 AU AU2022302809A patent/AU2022302809A1/en active Pending
- 2022-06-30 MX MX2023012935A patent/MX2023012935A/es unknown
- 2022-06-30 US US18/565,628 patent/US20240293512A1/en active Pending
- 2022-06-30 WO PCT/KR2022/009449 patent/WO2023277620A1/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6076902B2 (ja) | 新規な持続型グルカゴン結合体およびこれを含む肥満の予防および治療用薬学的組成物 | |
| KR101201339B1 (ko) | 인간 ｅｐｏ 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도 | |
| KR101895047B1 (ko) | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 | |
| JP2020164534A (ja) | インスリン及びｇｌｐ−１／グルカゴン二重アゴニストを含む糖尿病治療用組成物 | |
| EP2505207B1 (en) | Modified exendins and uses thereof | |
| US8716221B2 (en) | Modified exendins and uses thereof | |
| EA038524B1 (ru) | Длительно действующий конъюгат тройного агониста рецепторов глюкагона/glp 1/gip | |
| JP2011001381A (ja) | Ｇｌｐ−１医薬組成物 | |
| KR20050033563A (ko) | 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도 | |
| JP2014520798A (ja) | ポリエチレングリコールまたはその誘導体でｐｅｇ化されたエキセンジン−４類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物 | |
| JP7762645B2 (ja) | バリアントｆｃドメイン及びその使用 | |
| CN118684758A (zh) | 肠促胰岛素类似物及其应用 | |
| JP2024178193A (ja) | インスリン及びグルカゴンを含む薬学組成物 | |
| JP2024500605A5 (https=) | ||
| JP2024525213A5 (https=) | ||
| JP2024527220A5 (https=) | ||
| JP2024507795A (ja) | グルカゴン様ペプチド－１受容体アンタゴニスト | |
| JP2023538236A5 (https=) | ||
| CN116635050A (zh) | 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途 | |
| CN106163569B (zh) | 活化的神经降压素分子及其用途 | |
| JP2023537895A5 (https=) | ||
| WO2025157263A1 (zh) | 偶联物及其制备方法和用途 | |
| EP4364750A1 (en) | Therapeutic use of combination comprising triple activator having activity on all of glucagon, glp-1 and gip receptor | |
| JP2024503242A (ja) | 短腸症候群の予防又は治療のためのインスリン分泌ペプチドとｇｌｐ－２の併用療法 | |
| JP2024512895A (ja) | グルカゴン誘導体を含む慢性腎臓疾患予防又は治療用薬学組成物 |